Sobriety restrictions on hepatitis C treatment raise healthcare costs
People with hepatitis C in the U.S. who are insured through state Medicaid programs that require them to be sober to access treatment are…
Marisa Wexler, MS, Senior Science Writer — 
Articles by Marisa Wexler
Linerixibat reduces itch, improves sleep in PBC Phase 3 trial
Nearly six months of treatment with the experimental oral candidate linerixibat significantly reduced itch and itch-related sleep problems for adults with primary biliary cholangitis…
MASLD in pregnancy tied to higher risk of premature birth: Study
Women with metabolic dysfunction-associated steatotic liver disease (MASLD), a form of fatty liver disease, are more likely to give birth prematurely, but their babies…
Even with past treatment, Livdelzi works on primary biliary cholangitis
The efficacy of Livdelzi (seladelpar) at treating primary biliary cholangitis (PBC) is similar irrespective of whether patients previously received other medications, according to…
RTY-694 shows promise in models of liver, bile duct diseases PFIC, PSC
An experimental oral therapy by Rectify Pharmaceuticals called RTY-694 reduced markers of slowed bile flow and inflammation in a mouse model of progressive…
Children with fatty liver disease MASLD have higher mortality risk
Children with metabolic dysfunction-associated steatotic liver disease (MASLD), a form of fatty liver disease, are more than 40 times more likely to die than…
New primary sclerosing cholangitis treatment to target ACLY enzyme
With ESP-1336 as their lead candidate, Esperion Therapeutics is developing new treatments for primary sclerosing cholangitis (PSC) by targeting an enzyme called ACLY.
FDA, Health Canada reviewing semaglutide for liver disease MASH
The U.S. Food and Drug Administration and Health Canada are reviewing Novo Nordisk‘s requests to approve semaglutide’s under-the-skin formulation, at a dose of 2.4…
Statins reduce risk of liver cancer, death in chronic viral hepatitis
Treatment with certain types of cholesterol-lowering drugs called statins may help reduce the risk of cirrhosis, or irreversible liver scarring, liver cancer, and death in…
Boosting IRF1 protein prevents growth of hepatitis D virus in study
Increasing the levels of a protein called IRF1 helps suppress infection of the hepatitis D virus (HDV) and its growth inside of cells, a new…
